Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.cbcpharma.com | |
Market Cap | 72.66 Cr. | |
Enterprise Value(EV) | 88.03 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.06 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 91.20 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 32.00 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 33.68 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 2.86 | Calculated using Price: 96.30 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.75 Cr. | 7,545,056 Shares |
FaceValue | 10 | |
Company Profile | ||
The company is engaged in the marketing of lifesaving medicines in India such as Cardiovascular, Antineoplastic, Antibiotics and Hormones medicines. It provides pharmaceuticals and special chemical products in the Indian and international market. It has wide range of products portfolio of pharmaceutical formulation including IV & IM range Injections, few tablets to cater the Domestic & Export Market. |
1 Day |
|
|
1 Week |
|
|
1 Month |
|
-12.45% |
3 Month |
|
-14.78% |
6 Month |
|
-9.36% |
1 Year |
|
-7.54% |
2 Year |
|
+143.18% |
5 Year |
|
|
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 7.53 | 6.89 | 5.38 | 9.33 | 13.44 | 6.46 | 1.67 | 0.78 | 3.19 | |
Return on Capital Employed (%) | 11.66 | 10.40 | 12.62 | 14.34 | 17.58 | 13.40 | 7.16 | 7.63 | 8.83 | |
Return on Assets (%) | 1.27 | 1.16 | 0.82 | 1.32 | 1.82 | 0.98 | 0.40 | 0.26 | 1.10 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Shh. Funds | 3 | 6 | 6 | 7 | 7 | 8 | 14 | 26 | 26 | 27 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 11 | 21 | 16 | 15 | 13 | 8 | |
Curr. Liab. | 21 | 26 | 36 | 38 | 37 | 29 | 53 | 34 | 33 | 38 | |
Minority Int. | |||||||||||
Equity & Liab. | 24 | 32 | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | |
Non Curr. Assets | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |
Curr. Assets | 23 | 31 | 41 | 44 | 55 | 57 | 81 | 73 | 70 | 71 | |
Misc. Exp. not W/O | 0 | 1 | 1 | 1 | 1 | ||||||
Total Assets | 24 | 32 | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Net Sales | 35 | 48 | 61 | 80 | 90 | 97 | 106 | 94 | 71 | 94 | |
Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | ||
Total Income | 35 | 49 | 61 | 80 | 90 | 98 | 107 | 94 | 71 | 96 | |
Total Expenditure | -35 | -46 | -58 | -76 | -85 | -92 | -102 | -91 | -67 | -91 | |
PBIDT | 0 | 2 | 3 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | |
Interest | -2 | -2 | -4 | -4 | -4 | -4 | -3 | -4 | -3 | ||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Taxation | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | |
Exceptional Items | |||||||||||
PAT | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | |
Adjusted EPS | 9 | 8 | 10 | 8 | 2 | 3 | 1 | 0 | 0 | 1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -9 | -6 | 4 | -7 | 8 | 12 | |||||
Cash Fr. Inv. | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Cash Fr. Finan. | 8 | 7 | -4 | 7 | -6 | -10 | |||||
Net Change | -1 | 0 | 0 | 0 | 2 | 3 | |||||
Cash & Cash Eqvt | 1 | 1 | 0 | 0 | 3 | 6 |
Mon, 14 Nov 2022
Approval Of Un-Audited Financial Result As On 30Th September 2022. Approval of Un-Audited Financial Result as on 30th September 2022. |
Mon, 14 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th November 2022 For Approval Of Un-Audited Financial Result As On 30Th September 2022. Outcome of Board Meeting held on 14th November 2022 for approval of Un-Audited Financial Result as on 30th September 2022. |
Mon, 07 Nov 2022
Board Meeting Intimation for Approval Of Un-Audited Financial Result As On 30.09.2022. Chandra Bhagat Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve Un-Audited Financial Result as on 30.09.2022 and any other Business. |
Tue, 21 Mar 2023 |
|
|
|
|
|